跳到主要导航
跳到搜索
跳到主要内容
Pure University (For Demo Only) 国内
帮助和常见问题
English
中文
国内
简介
研究单位
科研成果
设备
数据集
活动
奖项
影响
项目
新闻 / 媒体
按专业知识、名称或附属进行搜索
Anti-inflammatory medications for obstructive sleep apnoea in children
Stefan Kuhle
, Dorle U. Hoffmann,
Souvik Mitra
, Michael S. Urschitz
科研成果
:
期刊稿件
›
文献综述
›
同行评审
59
引用 （Scopus）
综述
指纹
指纹
探究 'Anti-inflammatory medications for obstructive sleep apnoea in children' 的科研主题。它们共同构成独一无二的指纹。
分类
加权
按字母排序
Keyphrases
Absence of Evidence
8%
Adenoid Hypertrophy
16%
Adenoids
16%
Adenotonsillectomy
8%
Adverse Events
16%
Airway
8%
Anti-inflammatory Drugs
100%
Apnea-hypopnea
8%
Apnea-hypopnea Index
50%
Arousal Index
33%
Beneficial Effects
8%
Clinical Significance
8%
Clinical Symptoms
8%
Cochrane
8%
Concentration Ability
8%
Data Extraction
8%
Data Quality
8%
Desaturation Index
33%
Efficacy Data
8%
Evenly Distributed
8%
Follow-up Time
8%
Intranasal Corticosteroids
25%
Intranasal Steroids
16%
Less Invasive
8%
Long-term Efficacy
8%
Long-term Safety
16%
Lower Respiratory
8%
Lymphoid Tissue
8%
MEDLINE
8%
Meta-analysis
8%
Minimal Clinically Important Difference
8%
Moderate to Severe
16%
Montelukast
58%
Nasal Bleeding
8%
Non-obese
8%
Non-surgical Treatment
8%
Obstructive Sleep Apnea
100%
Ongoing Clinical Trials
8%
Oxygen Saturation
41%
Patient-centered Outcomes
16%
Perioperative Risk
8%
Placebo
50%
Placebo Groups
25%
Polysomnography
8%
Quality Assessment
8%
Random Effects Model
8%
Randomized Controlled Trial
41%
Recurrence Rate
8%
Respiratory Disturbance Index
8%
Respiratory Effort-related Arousal
41%
Safety Data
8%
Saturation Avoidance
8%
School Performance
8%
Screening Data
8%
Search Methods
8%
Selection Criteria
8%
Selective Reporting
8%
Serious Adverse Events
8%
Sleep Medicine
8%
Surgical Removal
8%
Surgical Treatment
25%
Surgical Treatment of Obstructive Sleep Apnea
41%
Surgical Treatment Options
8%
Symptom Score
8%
Tertiary Care Hospital
8%
Tonsil
16%
Tonsillar
8%
Treatment Effect
25%
Underlying Risk Factors
8%
Upper Airway Obstruction
8%
Vigilantism
8%
World Health Organization
8%
Medicine and Dentistry
Adenoid
11%
Adenotonsillar Hypertrophy
11%
Adenotonsillectomy
5%
Adverse Event
17%
Alertness
5%
Anti-Inflammatory Drug
100%
Antiinflammatory Agent
17%
Apnea
41%
Carbetimer
5%
Clinical Trial
5%
Conservative Treatment
5%
Drug Therapy
100%
Epistaxis
5%
Fatty Acid Desaturation
23%
Hypopnea
41%
K-Complex
29%
Lymphatic Tissue
5%
Meta-Analysis
5%
Minimal Clinically Important Difference
5%
Montelukast
41%
Obstructive Sleep Apnea
100%
Oxygen Saturation
29%
Placebo
52%
Polysomnography
5%
Random Effects Model
5%
Randomized Controlled Trial
29%
Recurrence Risk
5%
Respiratory Disturbance Index
5%
Sleep Medicine
5%
Surgery
17%
Symptom
5%
Tertiary Care
5%
Tonsil
11%
Treatment Effect
17%
Upper Respiratory Tract Obstruction
5%
Pharmacology, Toxicology and Pharmaceutical Science
Adenotonsillar Hypertrophy
11%
Adverse Event
17%
Anti-Inflammatory Drug
100%
Antiinflammatory Agent
17%
Apnea
41%
Carbetimer
5%
Clinical Trial
5%
Epistaxis
5%
Montelukast
41%
Placebo
52%
Random Effects Model
5%
Randomized Controlled Trial
29%
Recurrence Risk
5%
Respiratory Failure
5%
Sleep Disordered Breathing
100%
Sleep Medicine
5%
Symptom
5%
Upper Respiratory Tract Obstruction
5%
Neuroscience
Adenoid
11%
Anti-Inflammatory
100%
Lymphatic Tissue
5%
Meta-Analysis
5%
Montelukast
41%
Obstructive Sleep Apnea
100%
Oxygen Saturation
29%
Placebo
52%
Polysomnography
5%
Randomized Controlled Trial
29%
Sleep Medicine
5%
Tonsil
11%
Vigilance
5%